The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > REGULATORY
REGULATORY
- Don’t Use Long-Listed Drugs, Dispense Generics: LDP Project Team
November 21, 2014
- Chuikyo OKs NHI Price Listing of 14 APIs/15 Products
November 20, 2014
- MHLW Will Rack Its Brain about How to Eke Out Social Security Funds: Shiozaki
November 20, 2014
- 3 Straight Years of NHI Price Cuts Loom as Abe Delays Sales Tax Hike, Eyes Now Turned to 2019 and Beyond
November 19, 2014
- MHLW OKs 4 Products Including New Indication for Spiriva
November 19, 2014
- Health Ministry Drug Evaluation Head Calls for Mulling Necessity of PI Studies for Japanese Patients
November 18, 2014
- Only Advantage of Authorized Generics is that “They Can Be Sold Earlier”: Prof. Ogata
November 18, 2014
- PAFSC 2nd Committee to Discuss Novartis’s Secukinumab on Nov. 28
November 18, 2014
- Editor’s Pick: Five Healthcare News Headlines for Nov. 4 - 14
November 17, 2014
- MHLW Official Says Penalty Rule Needs Review, Frowns on Sanguine Outlook for Annual Drug Price Cut
November 17, 2014
- PMDA to Accept All Requests for Generic Drug Face-to-Face Consultations
November 17, 2014
- MHLW to Report Poteligeo’s Additional Indication of Untreated CCR4-Positive ATL to PAFSC 2nd Committee on Nov. 28
November 17, 2014
- PMDA Looks to New Pre-Application Meetings to Shed Review Time
November 14, 2014
- New Japan NIH Head Asks Pharma Industry to Suggest Ideas for Benefit of Japanese People
November 13, 2014
- PMDA to Expand Consultation Services for Clinical Trials Initiated by Academia
November 12, 2014
- Blue, Yellow Letters to Cover Regenerative Medicines
November 11, 2014
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- PAFSC First Committee to Discuss Takeda’s Vonoprazan on Nov. 21
November 11, 2014
- US FDA Withdraws Tentative Approvals for 2 Generic Drugs of Ranbaxy
November 11, 2014
- 5 Experts Likely to Review Regenerative Medicines for Expedited Senshin-Iryo Scheme
November 10, 2014
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…